Cargando…

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK+ disease. Several randomized trials have proven tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spitaleri, Gianluca, Trillo Aliaga, Pamela, Attili, Ilaria, Del Signore, Ester, Corvaja, Carla, Corti, Chiara, Crimini, Edoardo, Passaro, Antonio, de Marinis, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217667/ https://www.ncbi.nlm.nih.gov/pubmed/37232842 http://dx.doi.org/10.3390/curroncol30050384

Ejemplares similares

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
por: Attili, Ilaria, et al.
Publicado: (2023)

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
por: Attili, Ilaria, et al.
Publicado: (2022)

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
por: Passaro, Antonio, et al.
Publicado: (2021)

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
por: Spitaleri, G., et al.
Publicado: (2023)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey
por: Catania, Chiara, et al.
Publicado: (2020)

Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model
por: de Marinis, Filippo, et al.
Publicado: (2020)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
por: Reclusa, Pablo, et al.
Publicado: (2019)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
por: Imamura, Fumio, et al.
Publicado: (2016)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
por: Dai, Ying, et al.
Publicado: (2018)

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
por: Alidousty, Christina, et al.
Publicado: (2018)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report
por: Wang, Wenxian, et al.
Publicado: (2016)

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
por: Passaro, Antonio, et al.
Publicado: (2021)

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
por: Gadgeel, Shirish, et al.
Publicado: (2018)

Testing for COVID-19 in lung cancer patients
por: Passaro, A., et al.
Publicado: (2020)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Refining precision cancer therapy in ALK-positive NSCLC
por: Lin, Jessica J., et al.
Publicado: (2019)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
por: Catania, Chiara, et al.
Publicado: (2014)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_av0jnbj4r69qbn43d3lis3qopp